Focus:
All articles by Praveen Duddu
-
Deals this week: Vistin Pharma, Shenzhen Neptunus Bioengineering
Vistin Pharma plans to raise up to Nkr300m ($38.82m) in gross proceeds through a private placement of shares of its common…
23 Mar
Read More… -
M&As this week: Otsuka Pharmaceutical Factory, Shin Kowa Pharmaceutical
Otsuka Pharmaceutical Factory has reached an agreement with Mitsui & Co to acquire a remaining 20% interest in Otsuka Pharmaceutical India…
23 Mar
Read More… -
Deals and M&As this week: Zydus Cadila Healthcare, Eisai, Tabuk Pharmaceuticals Manufacturing Company
Zydus Cadila Healthcare has signed an agreement with Medicure’s subsidiary Medicure International for the commercialisation of its ZYPITAMAG (pitavastatin magnesium) drug,…
9 Mar
Read More… -
Deals this week: ExpreS2ion Biotech Holding, Arbutus Biopharma, Intrexon
ExpreS2ion Biotech Holding, a biopharmaceutical company based in Denmark, intends for a rights offering of 2,400,403 shares at a price…
19 Jan
Read More… -
Deals this week: China Meheco, Recordati, Novartis
China Meheco intends to form a Chinese pharmaceutical joint venture (JV) through its subsidiary with a capital of CNY10m ($1.51m). To…
22 Dec
Read More… -
M&As this week: Strides Pharma Asia, GlaxoSmithKline
Strides Pharma Asia has agreed to purchase a 55% stake in South African pharmaceutical company Trinity Pharma for R55m ($4.31m)….
22 Dec
Read More… -
Report: Multiple sclerosis disease-modifying therapies market to witness CAGR of 2.9%
Sales of multiple sclerosis (MS) disease-modifying therapies (DMTs) are projected to grow from $19.1bn in 2016 to $25.3bn in 2026,…
15 Dec
Read More… -
Deals this week: Revance Therapeutics, GW Pharmaceuticals, Valeant Pharmaceuticals International
Revance Therapeutics intends to raise $175m through an underwritten public offering of the shares of its common stock. Underwriters will…
8 Dec
Read More… -
M&As this week: CVS Health Corporation, NeuroSearch
CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn….
8 Dec
Read More… -
Deals this week: Eris Lifesciences, Sichuan Languang Development, Xiangxue Pharmaceutical, Navamedic
Eris Lifesciences has reached an agreement to purchase Strides Shasun’s Indian generics business for $76.73m. Under the agreement, Eris will take…
24 Nov
Read More…
Go Top
